Dipna Pharmaceuticals Ltd. engages in the trading and distribution of pharmaceutical raw material and chemical formulation products. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2022-09-08. The firm's product portfolio comprises approximately 61 APIs and AIPs intermediates, such as Cephalosporins, Cardiovasculars, Anti - Bactaria, Quinolones, Veterinary, Anti - Virus, Anti - Inflammatory, Neuropsychiatry, Steroid Hormone and others. Its products include Aceclofenac, Asprin, Acetazolamide, Albendazole, Ambroxol HCL, Amisulpride IP/BP, Amoxicillin, Aripiprazole IP, Artemether, Azithromycin, Hydrocortisone Acetate, Ibuprofen Ip, Levofloxacin. Lumefantrine, Lidocaine Base, Lidocaine Hydrochloride, Lornoxicam, L Glutathione Reduced, L Glutamine, L Carnosine, L Arginine Base and others. The company provides import/export services to clients throughout the world.
Loading chart…
This company hasn't held an earnings call in the last six months, so there's no recent commentary from management. Our deep dives are built on what management actually said, so we haven't prepared one.
12 fields couldn't be derived. The company was scraped before the cash-flow and balance-sheet rows were captured. Re-running an analysis will refresh these.